A solution for the 59%
Nearly 5 million people are living with congestive heart failure in the United States today. Approximately 550,000 heart failure cases are diagnosed in the country each year, but the wait for a safe, revolutionary solution is finally over. The FDA-approved BAROSTIM NEO is providing significant clinical benefit to those patients suffering from heart failure symptoms. Minimally invasive, clinically-proven effective, and recommended by world-class physicians, BAROSTIM NEO is helping the 59% of systolic heart failure patients—who have been living with an unmet need—lead more active, higher quality, and healthier lifestyles.